BridgeBio Pharma BBIO Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $194.52M+26.2% | $154.18M+27.7% | $120.7M+9.2% | $110.57M-5.2% | $116.63M+1,883% | ||
| $9.94M+22.6% | $8.11M+23.5% | $6.56M+79.7% | $3.65M+38.4% | $2.64M+26.6% | ||
| $184.58M+26.4% | $146.07M+28.0% | $114.14M+6.8% | $106.91M-6.2% | $113.99M+2,901% | ||
| 94.9%+0.1pp | 94.7%+0.2pp | 94.6%-2.1pp | 96.7%-1.0pp | 97.7%+33.2pp | ||
| $126.64M+8.8% | $116.42M+3.1% | $112.87M+1.5% | $111.23M-0.2% | $111.43M-14.5% | ||
| $163.9M+3.7% | $158.09M+14.9% | $137.62M+6.6% | $129.15M+21.4% | $106.37M+12.2% | ||
| $300.47M+2.3% | $293.74M+10.5% | $265.9M+8.6% | $244.84M+10.8% | $221.01M-4.7% | ||
| -$105.96M+24.1% | -$139.56M+3.9% | -$145.2M-8.1% | -$134.28M-28.7% | -$104.37M+53.8% | ||
| -54.5%+36.0pp | -90.5%+29.8pp | -120.3%+1.1pp | -121.4%-32.0pp | -89.5%+3,753pp | ||
| $12.94M+11.2% | $11.64M-0.9% | $11.74M-68.8% | $37.64M+108% | $18.12M-15.8% | ||
| $6.25M+44.2% | $4.33M-30.6% | $6.24M+60.1% | $3.9M-27.6% | $5.39M+15.0% | ||
| -$60.6M-9.8% | -$55.19M-33.7% | -$41.28M+12.9% | -$47.38M+27.4% | -$65.24M— | ||
| -$18.28M+13.1% | -$21.03M-32.8% | -$15.83M+21.6% | -$20.19M-29.8% | -$15.56M+6.8% | ||
| $0— | $0— | $0— | $0+100% | -$21.16M— | ||
| -$166.56M+14.4% | -$194.64M-5.2% | -$184.94M-0.6% | -$183.76M-8.3% | -$169.61M+36.6% | ||
| -85.6%+40.6pp | -126.2%+27.0pp | -153.2%+13.0pp | -166.2%-20.8pp | -145.4%+4,400pp | ||
| -$0.84+15.2% | -$0.99-4.2% | -$0.950.0% | -$0.95-8.0% | -$0.88+38.0% | ||
| -$0.84+15.2% | -$0.99-4.2% | -$0.950.0% | -$0.95-8.0% | -$0.88+38.0% | ||
| 194.8M+1.7% | 191.5M-0.2% | 191.9M+0.7% | 190.5M+0.2% | 190.1M+2.2% | ||
| 194.8M+1.7% | 191.5M-0.2% | 191.9M+0.7% | 190.5M+0.2% | 190.1M+2.2% | ||
| $39.87M+3.1% | $38.68M+6.2% | $36.41M+39.9% | $26.03M+8.4% | $24.02M+189% | ||
| $4.25M-64.0% | $11.82M-28.2% | $16.46M+151% | $6.55M-20.4% | $8.23M+407% | ||
| $0-100% | $11.13M+25.9% | $8.84M+998% | $805K+41.2% | $570K-87.9% | ||
| $194.52M+26.2% | $154.18M+27.7% | $120.7M+9.2% | $110.57M-5.2% | $116.63M+1,883% | ||
| -$105.96M+24.1% | -$139.56M+3.9% | -$145.2M-8.1% | -$134.28M-28.7% | -$104.37M+53.8% | ||
| -$104.77M+24.1% | -$138.13M+3.9% | -$143.8M-8.2% | -$132.96M-29.0% | -$103.09M+54.1% | ||
| -$104.77M+24.1% | -$138.13M+3.9% | -$143.8M-8.2% | -$132.96M-29.0% | -$103.09M+54.1% | ||
| -53.9%+35.7pp | -89.6%+29.5pp | -119.1%+1.1pp | -120.3%-31.9pp | -88.4%+3,731pp | ||
| -$105.96M+24.1% | -$139.56M+3.9% | -$145.2M-8.1% | -$134.28M-28.7% | -$104.37M+53.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is BridgeBio Pharma's revenue?
- BridgeBio Pharma (BBIO) generated $580.0M in revenue over the trailing twelve months, up 355.2% year over year.
- Is BridgeBio Pharma profitable?
- BridgeBio Pharma is not currently profitable: it reported a net loss of $729.9M over the trailing twelve months, a -125.9% net margin.
- What are BridgeBio Pharma's profit margins?
- Gross margin is 95.1% and operating margin is -90.5%, with a -125.9% net margin.
- What is BridgeBio Pharma's earnings per share?
- BridgeBio Pharma's diluted EPS over the trailing twelve months is $-3.73.
- Where does BridgeBio Pharma's income statement data come from?
- Every line is extracted from BridgeBio Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
